Financial Daily from THE HINDU group of publications
Thursday, Apr 18, 2002

News
Features
Stocks
Port Info
Archives

Group Sites

Money & Banking - Credit Rating


`P1+' reaffirmed for Cipla, Pfizer CPs

Our Bureau

MUMBAI, April 17

CREDIT Rating Information Services of India Ltd (Crisil) has reaffirmed its `P1+' rating, (indicating highest safety) assigned to the Rs 15-crore commercial paper programme of Cipla Ltd and the Rs 30-crore commercial paper programme of Pfizer Ltd.

According to the press release, the ratings reflect the two company's strong position as leading players in the Rs 15,600 crore domestic pharmaceutical industry.

The rating for Cipla factors in the sales growth arising from successful new product launches as well as profitability margins that the company enjoys on account of process re-engineering capabilities and value-added specialty exports to developed markets.

Cipla has a presence in the anti-asthma, anti-infective, anti-AIDS and cardiovascular segments and a moderate presence in the anti-inflammatory and anti-ulcerants segments.

The rating for Pfizer reflects the strong business position complemented by a favourable financial risk profile characterised by healthy profitability and zero-debt. In addition to pharmaceuticals, which accounted for 82 per cent in Pfizer's turnover in 2001, the company also operates in the animal health industry (15 per cent of turnover in 2001).

Send this article to Friends by E-Mail

Stories in this Section
Enron shares as `collectibles'


Rupee recovers; gilts weak
RBI amends norms on forex contracts
Can Fin Homes ad gets clean chit
StanChart offers new home loan scheme
LIC info-centre in Mumbai
`P1+' reaffirmed for Cipla, Pfizer CPs
Centurion promoter Ahuja quits board
No rethink on rates
HSBC launches Internet merchant services


The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | The Sportstar | Frontline | Home |

Copyright 2002, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line